Skip to main content
. 2012 Mar 27;109(15):5797–5802. doi: 10.1073/pnas.1117208109

Fig. 4.

Fig. 4.

The relationship between NY-ESO-1-specific immune responses and clinical outcome in melanoma patients. (A) CD8+ T-cell response vs. PFS of melanoma patients. (B) CD8+ T-cell response vs. OS of melanoma patients. (C) Baseline seropositive patients with CD8+ T-cell reactivity demonstrated a significantly improved TTP (median, 19.5 mo) compared with other groups of patients.